Blue-light cystoscopy with Cysview® is the only FDA-approved technology for enhanced detection of bladder cancer, turning tumors bright pink during surgery. Pair it with our UH 400 surgical generator for optimal results.
Blue Light Cystoscopy with Cysview® is the only FDA-approved technology for enhanced detection of bladder cancer. Use flexible cystoscopy for ongoing surveillance, and rigid cystoscopy for resection. Learn more here.
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.
Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.
Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.
Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.
Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.
Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.
Here to Help
As a leader in minimally invasive surgical devices, KARL STORZ offers complete urology solutions that combine sophisticated telescopes and advanced precision instruments. Flagship products include high-frequency surgical devices, components for laser surgery, lithotripsy devices for stone detection and removal, rigid and flexible telescopes for procedures in the ureter, flexible video endoscopes, and specialized equipment for photodynamic diagnostics. Our extensive product line includes instruments specifically designed for pediatric patients.
The products described in the videos, images, and documents on this site have been approved authorized by the company for use in the United States only. The materials on this site are provided exclusively as an educational service for medical professionals and do not necessarily reflect the views of KARL STORZ Endoscopy-America, Inc. The decision to apply any of the information on this site is at the sole discretion and choice of qualified medical personnel, who are advised to verify the applicability and the suitability for any particular situation. KARL STORZ cannot be held is not responsible for the misuse of any information on this site.